These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 4026361

  • 1. Wilson's disease: assessment of D-penicillamine treatment.
    Van Caillie-Bertrand M, Degenhart HJ, Luijendijk I, Bouquet J, Sinaasappel M.
    Arch Dis Child; 1985 Jul; 60(7):652-5. PubMed ID: 4026361
    [Abstract] [Full Text] [Related]

  • 2. Oral zinc sulphate for Wilson's disease.
    Van Caillie-Bertrand M, Degenhart HJ, Visser HK, Sinaasappel M, Bouquet J.
    Arch Dis Child; 1985 Jul; 60(7):656-9. PubMed ID: 4026362
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Value of urinary copper excretion after penicillamine challenge in the diagnosis of Wilson's disease.
    Martins da Costa C, Baldwin D, Portmann B, Lolin Y, Mowat AP, Mieli-Vergani G.
    Hepatology; 1992 Apr; 15(4):609-15. PubMed ID: 1551638
    [Abstract] [Full Text] [Related]

  • 5. The pattern of urinary copper excretion and its response to treatment in patients with Wilson's disease.
    Walshe JM.
    QJM; 2011 Sep; 104(9):775-8. PubMed ID: 21622540
    [Abstract] [Full Text] [Related]

  • 6. Zinc sulphate therapy for Wilson's disease after acute deterioration during treatment with low-dose D-penicillamine.
    Veen C, van den Hamer CJ, de Leeuw PW.
    J Intern Med; 1991 Jun; 229(6):549-52. PubMed ID: 2045766
    [Abstract] [Full Text] [Related]

  • 7. The treatment of Wilson's disease with zinc. IV. Efficacy monitoring using urine and plasma copper.
    Brewer GJ, Hill G, Prasad A, Dick R.
    Proc Soc Exp Biol Med; 1987 Apr; 184(4):446-55. PubMed ID: 3562454
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Urinary excretion of copper, zinc and iron with and without D-penicillamine administration in relation to hepatic copper concentration in dogs.
    Fieten H, Hugen S, van den Ingh TS, Hendriks WH, Vernooij JC, Bode P, Watson AL, Leegwater PA, Rothuizen J.
    Vet J; 2013 Aug; 197(2):468-73. PubMed ID: 23583003
    [Abstract] [Full Text] [Related]

  • 10. Long-term evaluation of urinary copper excretion and non-caeruloplasmin associated copper in Wilson disease patients under medical treatment.
    Pfeiffenberger J, Lohse CM, Gotthardt D, Rupp C, Weiler M, Teufel U, Weiss KH, Gauss A.
    J Inherit Metab Dis; 2019 Mar; 42(2):371-380. PubMed ID: 30746719
    [Abstract] [Full Text] [Related]

  • 11. Mode of action of triethylenetetramine dihydrochloride on copper metabolism in Wilson's disease.
    Siegemund R, Lössner J, Günther K, Kühn HJ, Bachmann H.
    Acta Neurol Scand; 1991 Jun; 83(6):364-6. PubMed ID: 1887758
    [Abstract] [Full Text] [Related]

  • 12. Maintenance zinc therapy after initial penicillamine chelation to treat symptomatic hepatic Wilson's disease in resource constrained setting.
    Gupta P, Choksi M, Goel A, Zachariah U, Sajith KG, Ramachandran J, Chandy G, Kurian G, Rebekah G, Eapen CE.
    Indian J Gastroenterol; 2018 Jan; 37(1):31-38. PubMed ID: 29457214
    [Abstract] [Full Text] [Related]

  • 13. [Appropriate administration schedule of D-penicillamine for pediatric Wilson's disease patients based on urinary copper excretion].
    Fukuoka N, Morita S, Hamatani S, Okada H, Kondoh M, Imai T, Ohnishi S, Itoh S.
    Yakugaku Zasshi; 2002 Aug; 122(8):585-8. PubMed ID: 12187774
    [Abstract] [Full Text] [Related]

  • 14. Practical recommendations and new therapies for Wilson's disease.
    Brewer GJ.
    Drugs; 1995 Aug; 50(2):240-9. PubMed ID: 8521757
    [Abstract] [Full Text] [Related]

  • 15. Treatment of Wilson's disease with zinc: XV long-term follow-up studies.
    Brewer GJ, Dick RD, Johnson VD, Brunberg JA, Kluin KJ, Fink JK.
    J Lab Clin Med; 1998 Oct; 132(4):264-78. PubMed ID: 9794697
    [Abstract] [Full Text] [Related]

  • 16. Urinary copper excretion and hepatic copper concentrations in liver disease.
    Frommer DJ.
    Digestion; 1981 Oct; 21(4):169-78. PubMed ID: 7215719
    [Abstract] [Full Text] [Related]

  • 17. Penicillamine hepatotoxicity in the treatment of Wilson's disease.
    Menara M, Zancan L, Sturniolo GC.
    J Pediatr Gastroenterol Nutr; 1992 Apr; 14(3):353-4. PubMed ID: 1619543
    [No Abstract] [Full Text] [Related]

  • 18. Low-dose zinc administration as an effective Wilson's disease treatment.
    Najda J, Stella-Hołowiecka B, Machalski M.
    Biol Trace Elem Res; 2001 Jun; 80(3):281-4. PubMed ID: 11508632
    [Abstract] [Full Text] [Related]

  • 19. [Oral zinc in Wilson disease--an alternative to D-penicillamine].
    Ramadori G, Keidl E, Hütteroth T, Dormeyer HH, Manns M, Meyer zum Büschenfelde KH.
    Z Gastroenterol; 1985 Jan; 23(1):25-9. PubMed ID: 4060799
    [Abstract] [Full Text] [Related]

  • 20. Oral zinc therapy for Wilson's disease.
    Brewer GJ, Hill GM, Prasad AS, Cossack ZT, Rabbani P.
    Ann Intern Med; 1983 Sep; 99(3):314-9. PubMed ID: 6614680
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.